Sagimet director granted 39,567 stock options

Sagimet Biosciences director Beth C. Seidenberg received a grant of stock options covering 39,567 shares of Series A common stock on June 12, 2026.

Rhea-AI Filing Summary

Sagimet Biosciences director Beth C. Seidenberg received a grant of stock options covering 39,567 shares of Series A common stock on June 12, 2026. The options have an exercise price of $6.48 per share and expire on June 11, 2036.

These options were awarded as a compensation grant, not a market purchase or sale. According to the terms, the underlying shares will vest in twelve equal monthly installments after June 12, 2026, as long as she continues serving the company on each vesting date.

Insider Trade Summary

Grant/Award: 39,567 shares

Grant/Award 1 txn

Insider SEIDENBERG BETH C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	39,567	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 39,567 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option grant size: 39,567 options Exercise price: $6.48 per share Expiration date: June 11, 2036 +2 more

5 metrics

Option grant size 39,567 options Stock Option (Right to Buy) granted June 12, 2026

Exercise price $6.48 per share Strike price for Series A common stock options

Expiration date June 11, 2036 Option term for director grant

Underlying shares 39,567 shares Series A common stock underlying the options

Vesting schedule 12 equal monthly installments Monthly vesting after June 12, 2026, subject to continued service

Key Terms

Stock Option (Right to Buy), Series A Common Stock, exercise price, vesting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Series A Common Stock financial

"underlying_security_title: Series A Common Stock"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

exercise price financial

"conversion_or_exercise_price: 6.4800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sagimet Biosciences (SGMT) report for Beth C. Seidenberg?

Sagimet Biosciences reported that director Beth C. Seidenberg received a grant of stock options for 39,567 shares of Series A common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What are the key terms of Beth C. Seidenberg’s Sagimet (SGMT) stock option grant?

The option grant covers 39,567 shares of Sagimet Series A common stock at an exercise price of $6.48 per share. The options expire on June 11, 2036, providing a long-dated incentive aligned with the company’s future performance.

How do Beth C. Seidenberg’s Sagimet (SGMT) options vest over time?

The shares underlying the option will vest in twelve equal monthly installments following June 12, 2026. Vesting is conditioned on Beth C. Seidenberg’s continued service with Sagimet Biosciences on each monthly vesting date, typical for director equity compensation.

Did Beth C. Seidenberg buy or sell Sagimet (SGMT) shares in this Form 4?

No open-market buy or sell occurred. The Form 4 shows a grant of stock options as compensation, not a purchase or sale of existing shares. The transaction direction is classified as an acquisition through grant or award.

How many Sagimet (SGMT) derivative securities does Beth C. Seidenberg hold after this grant?

After this grant, Beth C. Seidenberg holds 39,567 stock options according to the filing’s totals. These options each relate to one share of Series A common stock, providing potential future ownership if exercised at the $6.48 strike price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SEIDENBERG BETH C

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CALIFORNIA 94402

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.48	06/12/2026		A		39,567		(1)	06/11/2036	Series A Common Stock	39,567	$0	39,567	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Elizabeth Rozek, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)